BTX : Summary for BioTime, Inc. Common Stock - Yahoo Finance

U.S. Markets closed

BioTime, Inc. (BTX)

NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
3.32+0.11 (+3.43%)
At close: 4:00PM EST
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close3.21
Bid0.00 x
Ask0.00 x
Day's Range3.21 - 3.37
52 Week Range2.02 - 4.01
Avg. Volume247,150
Market Cap343.26M
PE Ratio (TTM)12.62
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Business Wire2 days ago

    Additional Data From BioTime’s OpRegen® Clinical Trial in Dry-AMD to be Presented at ARVO 2017

    BioTime, Inc. , a clinical stage biotechnology company with a focus on pluripotent stem cell technologies, and its subsidiary, Cell Cure Neurosciences, Ltd., today announced that an abstract evaluating OpRegen® in patients with advanced dry Age-Related Macular Degeneration based on the ongoing Phase I/IIa clinical trial will be presented at the Association for Research in Vision and Opthalmology meeting ...

  • BioTime, Inc. breached its 50 day moving average in a Bearish Manner : BTX-US : January 12, 2017
    Capital Cube9 days ago

    BioTime, Inc. breached its 50 day moving average in a Bearish Manner : BTX-US : January 12, 2017

    Categories: ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for BioTime, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average ... Read more (Read more...)

  • Business Wire18 days ago

    BioTime and Subsidiary Cell Cure Neurosciences Establish Innovative Cell Therapy Manufacturing Center in Jerusalem, Israel

    BioTime, Inc.  , a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, and its majority-owned subsidiary, Cell Cure Neurosciences Ltd, today dedicated a new, 800 square meter , state-of-the-art, cGMP manufacturing center located in the Jerusalem Bio Park on the campus of Hadassah University Hospital in Jerusalem.